Globus Medical, Inc. GMED continues to benefit from ... In the fourth quarter, Globus' musculoskeletal sales improved 4.5% year over year. The growth was driven primarily by strong contributions ...

Barclays raised the firm’s price target on Globus Medical (GMED) to $103 from $100 and keeps an Overweight rating on the shares. The company’s Q4 sales growth of 7% equates to low- to mid ...

Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

Learn more about whether Globus Medical, Inc. or QuidelOrtho Corporation is a better investment based on AAII's A+ Investor ...

Globus Medical (NYSE:GMED – Get Free Report) had its target price dropped by investment analysts at Truist Financial from $90.00 to $82.00 in a research note issued to investors on Tuesday,Benzinga ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...

Globus Medical (NYSE:GMED – Get Free Report)‘s stock had its “hold” rating restated by equities researchers at Needham & ...

Globus Medical, Inc. has announced the commercial ... which may indicate that their market readiness is uncertain and could affect sales and adoption rates. The COHERE™ ALIF Spacer is made ...

Globus Medical, Inc. (NYSE:GMED) had a strong finish to 2024, achieving record sales of $657 million in Q4, a 7% increase from the previous year. Earnings per share (EPS) grew by 40% to $0.84 ...

Globus Medical has maintained a strong focus on innovation, launching 18 new products during 2024, with five introduced in the last quarter alone. The company’s Emerging Technology (ET) segment has ...

About Globus Medical, Inc. Based in Audubon ... surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce ...